{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=3", "query": { "intervention": "Chemotherapeutic Agent", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 599, "total_pages": 60, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapeutic+Agent&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T19:11:31.740Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01442714", "title": "Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 33, "start_date": "2011-08", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2018-01-03", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01442714" }, { "nct_id": "NCT06874335", "title": "A Phase 1 Study of BHV-1530 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "BHV-1530", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biohaven Therapeutics Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2025-03-20", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 17, "location_summary": "Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06874335" }, { "nct_id": "NCT04449549", "title": "Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Nilotinib and Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 82, "start_date": "2020-08-24", "completion_date": "2027-04-08", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04449549" }, { "nct_id": "NCT00795678", "title": "Chemotherapeutic Agents in Brain/Breast", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Metastatic Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinorelbine ditartrate", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2008-09", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 2, "location_summary": "New York, New York • Cleveland, Ohio", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795678" }, { "nct_id": "NCT02574533", "title": "Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma Recurrent", "Malignant Melanoma", "Melanoma" ], "interventions": [ { "name": "Vigil", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Gradalis, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2015-10", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 3, "location_summary": "Abilene, Texas • Dallas, Texas • Spokane, Washington", "locations": [ { "city": "Abilene", "state": "Texas" }, { "city": "Dallas", "state": "Texas" }, { "city": "Spokane", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574533" }, { "nct_id": "NCT02716038", "title": "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "MPDL3280A", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2016-06-07", "completion_date": "2022-10-01", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02716038" }, { "nct_id": "NCT01047293", "title": "RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 47, "start_date": "2010-05", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2017-04-04", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 2, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01047293" }, { "nct_id": "NCT00499109", "title": "Phase III of RRM1 & ERCC1 Directed Customized Chemotherapy for the Treatment of Patients With NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2007-05", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-07-09", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 7, "location_summary": "Lakeland, Florida • Leesburg, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Lakeland", "state": "Florida" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499109" }, { "nct_id": "NCT01562899", "title": "A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "BRAF Mutated Melanoma" ], "interventions": [ { "name": "MEK162", "type": "DRUG" }, { "name": "AMG 479", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2012-08-27", "completion_date": "2015-04-01", "has_results": false, "last_update_posted_date": "2020-12-10", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Salt Lake City, Utah", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01562899" }, { "nct_id": "NCT05198830", "title": "Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Adenocarcinoma", "Lung Large Cell Carcinoma", "Lung Non-Squamous Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Methoxyamine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-12-15", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-06T19:11:31.740Z", "location_count": 34, "location_summary": "Buena Park, California • Duarte, California • Irvine, California + 27 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05198830" } ] }